Biov Global Bhd, a regenerative medicine company, has become a substantial shareholder in Malaysian Genomics Resource Centre Bhd after acquiring an additional 4.317% stake, or 6.52 million shares, via a direct business transaction on Thursday.
Following the purchase, Biov Global’s total holding in the ACE Market-listed genomics and biopharmaceutical firm stands at 5.165%, surpassing the 5% disclosure threshold. The transaction value was not disclosed.
Biov Global is 27.12%-owned by Lim Kean Lam, with other shareholders including GM Biovalley Sdn Bhd (16.95%), Dr Wong Jeh Shyan (8.18%), Shing Yiu Fai (7.2%), and others.
Other substantial shareholders in MGRC include Proven Venture Capital (14.84%), Pixelvest Sdn Bhd PLT (6.33%), and executive chairman and managing director Leong Yien Hung (5.59%).
MGRC has reported losses for the past four financial years. For the year ended Dec 31, 2025, it posted a net loss of RM2.38 million on revenue of RM8.02 million. Shares in MGRC closed unchanged at 20 sen, valuing the company at RM30.19 million.
